<DOC>
	<DOCNO>NCT00214968</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability treatment PROVIGIL child adolescent excessive sleepiness ( ES ) associate narcolepsy obstructive sleep apnea/hypopnea syndrome ( OSAHS ) , administer 6 month .</brief_summary>
	<brief_title>Assess Safety Effectiveness PROVIGIL Treatment Children Adolescents With Excessive Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Inclusions Criteria : write informed consent/assent obtain meet minimal criterion establish International Classification Sleep Disorders ( ICSD ) manual American Academy Sleep Medicine ( AASM ) narcolepsy ( presumed narcolepsy ) OSAHS OR previous diagnosis narcolepsy OSAHS screen visit complaint ES good health determine medical psychiatric history , physical examination , ECG , clinical laboratory test blood pressure value great 5th percentile less 95th percentile National High Blood Pressure Education Program guideline blood pressure level boys girl age 6 16 year girls postmenarchal sexually active , negative urine pregnancy test screening , must use medically acceptable method birth control , must agree continue use method duration study ( 2 cycle participation study ) ; acceptable method birth control include : barrier method spermicide ; steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method ; intrauterine device ( IUD ) ; abstinence able swallow tablet similar size shape study drug tablet negative urine drug screen ( UDS ) illicit drug , alcohol ( ethanol ) , stimulant screen ; positive stimulant ( prescribed excessive sleepiness ) screening , UDS repeat washout period baseline parent legal representative willing participate study selfinduced sleep deprivation/poor sleep hygiene past present seizure disorder ( except history single febrile seizure ) , history psychosis , clinically significant head trauma ( eg , brain damage ) past neurosurgery history suicide attempt , suicidal risk clinically significant drug sensitivity stimulant amfetamine , dexamfetamine , methylphenidate ; and/or modafinil component use monoamine oxidase ( MAO ) inhibitor selective serotonin reuptake inhibitor ( SSRIs ) within 2 week baseline visit ( NOTE : SSRIs allow cataplexy patient stable dose least 1 month . ) receive investigational drug ( except modafinil ) within 4 week baseline visit disorder could interfere drug absorption , distribution , metabolism , excretion ( include previous gastrointestinal surgery ) active , clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematologic , neoplastic , endocrine , neurologic , immunodeficiency , pulmonary , major clinically significant disorder/disease clinically significant deviation normal range ( ) physical examination ECG finding , clinical laboratory test result ( ie , serum chemistry , hematology ) screen baseline visit absolute neutrophil count ( ANC ) low limit normal screening ( NOTE : If ANC low limit normal baseline visit , medical monitor consult continued eligibility study . ) history alcohol , narcotic , substance abuse pregnant lactating/nursing girl</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>